Quanterix CORP 8-K filings

Quanterix reported Q2 2026 revenue of $32.9 million, missing expectations, and revised its full-year revenue guidance downwards, while also extending its cash-flow break-even target to 2027.

Quanterix Corporation shareholders elected directors and ratified auditors but rejected the proposed amendment to the 2017 Equity Incentive Plan.

Quanterix Corporation announced the appointment of Jason Faessler as its new Chief Financial Officer and Treasurer, effective June 22, 2026, bringing extensive finance leadership experience from the life science tools industry.

Quanterix Corporation announced the appointment of Anthony Catalano as Chief Operating Officer and a leadership transition for Michael Miller.

Quanterix Corporation announced the planned departure of its Chief Financial Officer, Vandana Sriram, effective June 15, 2026, with a search for her successor underway.

Quanterix reported a 20% year-over-year revenue increase to $36.4 million for Q1 2026, driven by growth in its Alzheimer's diagnostics business and reaffirming its full-year guidance.

Quanterix announced its fourth quarter and full year 2025 financial results, reporting revenue stabilization and significant progress towards achieving cash flow breakeven in the second half of 2026.

Quanterix Corporation announced the appointment of Everett Cunningham as its new President and CEO, effective January 19, 2026, while also reporting expectations to exceed its revenue and cash guidance for the full year 2025.

Quanterix announces significant board and leadership changes, including new director appointments and an expanded role for the Executive Chair, to support its next phase of growth.

Quanterix Corporation announced third quarter 2025 financial results, meeting revenue expectations and progressing with Akoya integration to achieve cash flow break-even in 2026.

Quanterix Corporation stockholders approved all six proposals at their 2025 Annual Meeting, including significant corporate governance changes.

Quanterix Corporation adjourned its 2025 Annual Meeting of Stockholders to allow more time for votes on proposals to eliminate supermajority voting requirements, which had not yet reached the 75% threshold.

Quanterix Corporation filed an amendment to its 8-K report, providing unaudited pro forma financial statements for its recently completed acquisition of Akoya Biosciences, Inc.

Quanterix Corporation reported a 29% revenue decrease in Q2 2025, alongside a significant net loss, while also adopting a majority voting standard for uncontested director elections.

Quanterix Corporation has entered a cooperation agreement with activist investor Kent Lake, agreeing to board declassification, majority voting, and a new independent director.

Quanterix Corporation has committed to a termination plan to reduce operating costs and preserve cash, expecting $18.0 million in annualized savings following its acquisition of Akoya Biosciences, Inc.

Quanterix Corporation has committed to terminating certain executives at its newly acquired subsidiary, Akoya Biosciences, Inc., as part of an integration plan to achieve anticipated synergies and cost reductions.

Quanterix Corporation has successfully completed its acquisition of Akoya Biosciences, creating an integrated platform for ultra-sensitive biomarker detection across blood and tissue, significantly expanding its addressable market.

Quanterix Corporation has announced its 2025 Annual Meeting of Stockholders will be held virtually on September 23, 2025, leading to revised deadlines for shareholder proposals and director nominations.

Quanterix Corporation has dismissed Ernst & Young LLP and appointed KPMG LLP as its new independent registered public accounting firm, effective May 9, 2025.

Quanterix reports a 5% revenue decrease in Q1 2025, implements a cost reduction plan, and advances its merger with Akoya Biosciences.

Quanterix and Akoya Biosciences have revised their merger agreement, reducing the number of Quanterix shares to be issued and increasing the cash consideration for Akoya shareholders.

Quanterix Corporation has agreed to purchase up to $30 million in convertible promissory notes from Akoya Biosciences to support Akoya's working capital needs, contingent on certain conditions and the potential closing of their merger agreement.

Quanterix Corporation appoints William P. Donnelly as Chairman of the Board, succeeding Martin D. Madaus, who will resign following shareholder feedback and deferred action due to a potential strategic transaction.

Quanterix reports 11% revenue growth for Q4 2024 and announces a definitive merger agreement to acquire Akoya Biosciences in an all-stock transaction.

Quanterix emphasizes the strategic and financial advantages of acquiring Akoya Biosciences, projecting significant market expansion and synergy generation, while also addressing director nominations from Kent Lake Partners.

Quanterix Corporation's proposed merger with Akoya Biosciences has cleared the Hart-Scott-Rodino Antitrust Improvements Act waiting period, moving the acquisition closer to completion.

Quanterix Corporation's Compensation Committee approves the 2025 Annual Incentive Plan (AIP) for executive officers, linking payouts to financial, operational, and functional performance.

Quanterix reports preliminary unaudited Q4 2024 revenue of approximately $34.9 million and full year 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year, while also highlighting the pending acquisition of Akoya Biosciences.

Quanterix announced its plan to acquire Akoya Biosciences in a stock-for-stock transaction, aiming to create the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.